Liver Targeted Hyaluronate-Black Phosphorus Conjugate as a Copper Chelating Agent for Wilson Disease Treatment
발표자
()
초록
내용
Wilson disease (WD) is a genetic copper storage disorder, cause pathological accumulation of copper in the body. Usual Symptoms are related to the liver, but there have been only few studies of liver targeted WD treatment. New chelating agents, which can capture excess copper and simultaneously deliver to targeted liver, are highly required for WD therapy. Here, we developed a hyaluronate coated black phosphorus (HA-BP) conjugate for liver targeted delivery and copper capturing for the treatment of WD. HA enhanced stability and delivery efficiency of BP into liver cells. The HA-BP conjugates showed high liver-specific targeting efficiency, selectivity of copper capturing, excellent biocompatibility, and biodegradability. The liver-specific targeting efficiency was demonstrated through in vitro cellular uptake test. The biocompatibility and biodegradability of HA-BP conjugates are verified by cell viability test and absorbance spectrum. Taken together, these features make HA-BP can be efficient candidates of efficient copper chelating agent for WD treatment.